Recent Updates — ANAB

AnaptysBio reported financial results for the second quarter and transitional fiscal year ended June 30, 2026. The company posted net income from continuing operations of $177.3 million ($6.06 per share) for Q2 and $176.4 million ($6.09 per share) for the six-month period, driven by a $181.5 million tax benefit following the separation from First Tracks Biotherapeutics. Collaboration revenue reached $27.5 million in Q2 and $53.0 million year-to-date, reflecting 25% and 34% growth in Jemperli royalties respectively. Cash reserves stood at $164.1 million as of June 30. The company highlighted positive interim data from the AZUR-1 trial for dostarlimab, with an FDA PDUFA date set for February 2027, and anticipates a judgment in its litigation with GSK and Tesaro by Q4 2026 or Q1 2027. AnaptysBio operates as a biotechnology company focused on managing financial collaborations for licensed oncology and immunology assets.

On June 15, 2026, AnaptysBio, Inc. entered into a 12-month sublease agreement with First Tracks Biotherapeutics, Inc. for approximately 45,057 rentable square feet of space in San Diego, California. The sublease term commences on June 15, 2026, and includes a renewal option for First Tracks to extend the term until April 4, 2028. AnaptysBio, Inc. is a biotechnology company focused on developing therapeutic solutions.